Last reviewed · How we verify

NCT06374498

Study to Determine the Clinical Significance of Intravascular OCT-NIRAF

ENROLLING BY INVITATION NA Last updated 22 October 2025
What this trial tests

NA trial testing OCT-NIRAF in Cardiovascular Diseases in 40 participants. Enrolling by invitation.

Timeline
8 July 2024
Primary endpoint
30 April 2026
30 April 2027

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment40
Start date8 July 2024
Primary completion30 April 2026
Estimated completion30 April 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Cardiovascular Diseases or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will be imaged with OCT-NIRAF at baseline and with CCTA 12 months apart to demonstrate that: 1. NIRAF coronary artery signal level (patient, artery, lesion basis) is correlated with the severity of coronary artery disease. 2. NIRAF coronary artery signal level is a predictor of plaque progression on a per participant, per artery, or per lesion basis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06374498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing